

Eugene R Bleecker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4677882/publications.pdf>

Version: 2024-02-01

80
papers

13,456
citations

50276

46
h-index

56724

83
g-index

84
all docs

84
docs citations

84
times ranked

12257
citing authors

#	ARTICLE	IF	CITATIONS
1	German regional variation of acute and high oral corticosteroid use for asthma. <i>Journal of Asthma</i> , 2022, 59, 791-800.	1.7	5
2	Mapping geographic variability of severe uncontrolled asthma in the United States. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 78-88.	1.0	9
3	Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 871-881.	5.6	65
4	Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. <i>Journal of Asthma</i> , 2021, 58, 514-522.	1.7	30
5	Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. <i>Npj Biofilms and Microbiomes</i> , 2021, 7, 14.	6.4	33
6	Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 266-271.e2.	2.9	22
7	Pharmacogenetic studies of long-acting beta agonist and inhaled corticosteroid responsiveness in randomised controlled trials of individuals of African descent with asthma. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 862-872.	5.6	10
8	Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 276-293.	5.6	182
9	Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 60, 101881.	2.6	8
10	Response to mepolizumab treatment is sustained across 4-weekly dosing periods. <i>ERJ Open Research</i> , 2020, 6, 00068-2020.	2.6	4
11	Baseline sputum eosinophil+ neutrophil subgroups' clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 222-226.	2.9	25
12	Association of HLA-DRB1*09:01 with tlgE levels among African-ancestry individuals with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 147-155.	2.9	14
13	Exacerbation-prone asthma in the context of race and ancestry in Asthma Clinical Research Network trials. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1524-1533.	2.9	23
14	ADRB2 p.Thr164Ile association with hospitalization depends upon asthma severity. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1962-1965.e4.	2.9	3
15	Association study in African-admixed populations across the Americas recapitulates asthma risk loci in non-African populations. <i>Nature Communications</i> , 2019, 10, 880.	12.8	71
16	<p>Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma</p>. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 401-413.	3.4	28
17	Assembly of a pan-genome from deep sequencing of 910 humans of African descent. <i>Nature Genetics</i> , 2019, 51, 30-35.	21.4	276
18	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 46-59.	10.7	216

#	ARTICLE	IF	CITATIONS
19	Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. <i>Nature Genetics</i> , 2018, 50, 42-53.	21.4	426
20	Internet-Based Monitoring in the Severe Asthma Research Program Identifies a Subgroup of Patients With Labile Asthma Control. <i>Chest</i> , 2018, 153, 378-386.	0.8	6
21	Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. <i>Lancet Respiratory Medicine</i> , 2018, 6, 51-64.	10.7	220
22	Clinical Issues in Severe Asthma. <i>Chest</i> , 2018, 154, 982-983.	0.8	2
23	Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis. <i>Nature Genetics</i> , 2018, 50, 1072-1080.	21.4	106
24	Effects of endogenous sex hormones on lung function and symptom control in adolescents with asthma. <i>BMC Pulmonary Medicine</i> , 2018, 18, 58.	2.0	74
25	Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. <i>European Respiratory Journal</i> , 2018, 52, 1800936.	6.7	173
26	Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 545-554.e4.	3.8	210
27	Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. <i>Journal of Clinical Investigation</i> , 2018, 128, 997-1009.	8.2	337
28	Effects of bronchoscopy on lung function in asthmatics. <i>Journal of Asthma</i> , 2017, 54, 866-871.	1.7	3
29	Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. <i>Nature Genetics</i> , 2017, 49, 426-432.	21.4	306
30	Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 568-576.	10.7	99
31	Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1449-1463.	5.6	130
32	Characterisation of asthma subgroups associated with circulating YKL-40 levels. <i>European Respiratory Journal</i> , 2017, 50, 1700800.	6.7	48
33	Design of the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) AIR Study. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000186.	3.0	21
34	Airway Mucin Concentration as a Marker of Chronic Bronchitis. <i>New England Journal of Medicine</i> , 2017, 377, 911-922.	27.0	279
35	Biomarkers for severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1509-1518.	2.9	180
36	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , 2017, 5, 956-967.	10.7	211

#	ARTICLE	IF	CITATIONS
37	No genetic association detected with mepolizumab efficacy in severe asthma. <i>Respiratory Medicine</i> , 2017, 132, 178-180.	2.9	23
38	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPD Gene Cohorts. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 473-481.	5.6	101
39	Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1167-1175.e2.	2.9	78
40	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. <i>PLoS ONE</i> , 2017, 12, e0184606.	2.5	20
41	Asthma heterogeneity and severity. <i>World Allergy Organization Journal</i> , 2016, 9, 41.	3.5	73
42	Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. <i>Lancet Respiratory Medicine</i> , 2016, 4, 549-556.	10.7	433
43	Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , 2016, 388, 2128-2141.	13.7	1,070
44	Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β_2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. <i>Lancet</i> , 2016, 388, 2115-2127.	13.7	1,050
45	A continuum of admixture in the Western Hemisphere revealed by the African Diaspora genome. <i>Nature Communications</i> , 2016, 7, 12522.	12.8	136
46	Expression of asthma susceptibility genes in bronchial epithelial cells and bronchial alveolar lavage in the Severe Asthma Research Program (SARP) cohort. <i>Journal of Asthma</i> , 2016, 53, 775-782.	1.7	23
47	Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. <i>BMC Pulmonary Medicine</i> , 2016, 16, 65.	2.0	18
48	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. <i>PLoS Genetics</i> , 2016, 12, e1006011.	3.5	88
49	Impact of Age and Sex on Outcomes and Hospital Cost of Acute Asthma in the United States, 2011-2012. <i>PLoS ONE</i> , 2016, 11, e0157301.	2.5	57
50	Genome-wide association study and admixture mapping reveal new loci associated with total IgE levels in Latinos. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1502-1510.	2.9	52
51	Obstructive Sleep Apnea Risk, Asthma Burden, and Lower Airway Inflammation in Adults in the Severe Asthma Research Program (SARP) II. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 566-575.e1.	3.8	107
52	IL-6 trans-signaling increases expression of airways disease genes in airway smooth muscle. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L129-L138.	2.9	42
53	Phenotypic and genotypic association of epithelial IL1RL1 to human TH2-like asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 92-99.e10.	2.9	57
54	Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 9.	0.7	23

#	ARTICLE	IF	CITATIONS
55	Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. <i>Lancet Respiratory Medicine</i> , 2015, 3, 367-376.	10.7	153
56	Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 51-58.e10.	2.9	45
57	Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. <i>Lancet Respiratory Medicine</i> , 2015, 3, 849-858.	10.7	443
58	Asthma Is More Severe in Older Adults. <i>PLoS ONE</i> , 2015, 10, e0133490.	2.5	80
59	Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF ₂₅₋₇₅), Independently of FEV ₁ , in Adult Patients with Asthma. <i>PLoS ONE</i> , 2015, 10, e0145476.	2.5	49
60	Effect of Vitamin D ₃ on Asthma Treatment Failures in Adults With Symptomatic Asthma and Lower Vitamin D Levels. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2083.	7.4	236
61	Genome-wide interaction studies reveal sex-specific asthma risk alleles. <i>Human Molecular Genetics</i> , 2014, 23, 5251-5259.	2.9	70
62	GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 587-589.	2.9	43
63	Asthma heterogeneity and severity—why is comprehensive phenotyping important?. <i>Lancet Respiratory Medicine</i> , 2014, 2, 10-11.	10.7	16
64	Efficacy and safety of fluticasone furoate 100/4g once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial. <i>Respiratory Medicine</i> , 2014, 108, 41-49.	2.9	37
65	International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. <i>European Respiratory Journal</i> , 2014, 43, 343-373.	6.7	2,898
66	Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. <i>Lancet Respiratory Medicine</i> , 2014, 2, 879-890.	10.7	435
67	Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1557-1563.e5.	2.9	488
68	Fluticasone Furoate/Vilanterol 100-25 mcg Compared with Fluticasone Furoate 100 mcg in Asthma: A Randomized Trial. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 553-561.	3.8	40
69	Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β_2 agonist treatment in a multiethnic asthma population: a genetic study. <i>Lancet Respiratory Medicine</i> , 2014, 2, 204-213.	10.7	100
70	Asthma genetics and personalised medicine. <i>Lancet Respiratory Medicine</i> , 2014, 2, 405-415.	10.7	91
71	Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. <i>Npj Primary Care Respiratory Medicine</i> , 2014, 24, 14019.	2.6	23
72	Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 72-80.e12.	2.9	224

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma. <i>Chest</i> , 2013, 144, 1222-1229.	0.8	86
74	Characteristics of Perimenstrual Asthma and Its Relation to Asthma Severity and Control. <i>Chest</i> , 2013, 143, 984-992.	0.8	78
75	ADRB2 Polymorphisms and Budesonide/Formoterol Responses in COPD. <i>Chest</i> , 2012, 142, 320-328.	0.8	30
76	Effect of ADRB2 polymorphisms on response to longacting β_2 -agonist therapy: a pharmacogenetic analysis of two randomised studies. <i>Lancet</i> , 2007, 370, 2118-2125.	13.7	222
77	Salmeterol response is not affected by β_2 -adrenergic receptor genotype in subjects with persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 809-816.	2.9	147
78	Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. <i>International Journal of Cancer</i> , 2001, 95, 354-359.	5.1	48
79	Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. <i>Human Genetics</i> , 2001, 108, 430-435.	3.8	53
80	Estrogen Receptor Polymorphisms Associated With Enhanced Response of HDL to Estrogen Replacement Therapy in Postmenopausal Women. <i>Circulation</i> , 2001, 103, 1353-1353.	1.6	2